Garrison Point Advisors LLC Has $466,000 Stake in Agilent Technologies, Inc. (NYSE:A)

Garrison Point Advisors LLC lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 6.0% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,140 shares of the medical research company’s stock after selling 200 shares during the period. Garrison Point Advisors LLC’s holdings in Agilent Technologies were worth $466,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in A. Vanguard Group Inc. lifted its holdings in shares of Agilent Technologies by 18.2% during the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after acquiring an additional 4,605,228 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Agilent Technologies by 5.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after purchasing an additional 809,149 shares during the period. Champlain Investment Partners LLC bought a new stake in shares of Agilent Technologies in the 1st quarter valued at approximately $61,218,000. Finally, Marshall Wace LLP raised its holdings in shares of Agilent Technologies by 48.6% in the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock worth $124,073,000 after buying an additional 313,155 shares in the last quarter. Institutional investors own 87.42% of the company’s stock.

Insider Buying and Selling at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,995 shares of company stock valued at $1,739,510. 0.33% of the stock is currently owned by company insiders.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $130.72 on Friday. The business’s 50-day simple moving average is $140.91 and its 200 day simple moving average is $138.59. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The stock has a market cap of $38.14 billion, a price-to-earnings ratio of 30.90, a P/E/G ratio of 6.96 and a beta of 1.05. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the previous year, the company earned $1.43 EPS. Agilent Technologies’s revenue was down 5.6% on a year-over-year basis. As a group, research analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were issued a $0.236 dividend. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.72%. Agilent Technologies’s dividend payout ratio is presently 22.22%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on A shares. UBS Group upped their price target on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Stifel Nicolaus reiterated a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Evercore ISI boosted their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Citigroup raised their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, Bank of America boosted their target price on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.